About Marianna Koczywas
- Accolades
-
-
Pleural Mesothelioma
-
Pleural and Lung Cancer
-
Excellence in Research
-
Board Certified in Hematology
-
Koczywas has been a staff physician at City of Hope since 2001, specializing in thoracic oncology and diseases of the lungs, including pleural mesothelioma.
She is part of the lung cancer and head and neck cancer teams at City of Hope, which is a world leader in the treatment and research of several serious diseases. Its goal is providing patients with the opportunity to live longer and much better lives.
“For patients who have just been told they have cancer, I want them to know there is a place they can come, either for treatment, or to get the best opinion,” Koczywas said. “At City of Hope, we have a great team of people where these patients can receive the best possible care.”
Improving Treatment with Clinical Trials
Koczywas is the principal investigator in several ongoing clinical trials, including two specifically involving mesothelioma.
One is a phase II trial studying the novel immunotherapy drug tazemetostat as a second-line treatment. The early results have been impressive and were presented at the 2018 American Society of Clinical Oncology (ASCO) conference in Chicago.
The other trial she is heading at City of Hope is studying the effectiveness of methoxyamine, a small-molecule inhibitor, when used in combination with standard chemotherapy. Previous studies with methoxyamine have shown its ability to counteract a body’s natural resistance to chemotherapy.
“There has been a real unmet need [with mesothelioma],” she said. “The idea is to be smarter than the cancer cells. We’re trying to reverse the resistance to chemotherapy.”
A Believer in Personalized Therapy
Koczywas received her degree in 1984 from the Medical Academy of Lodz, in Lodz, Poland. She did a residency at St. Francis Medical Center in Pittsburgh.
She first came to City of Hope for fellowships that included the Department of Medical Oncology & Therapeutics Research and the Department of Hematology & Hematopoietic Cell Transplantation.
She also is an outspoken advocate for combining palliative care with cancer treatment programs early in the process.
Koczywas is a strong believer in personalized, targeted therapy for cancer patients, which fuels her passion for clinical trials.
See More Top Mesothelioma DoctorsDisclaimer: Dr. Marianna Koczywas has no professional affiliation with Asbestos.com.
Get the Best Treatment Options
Find a Doctor
Find a Mesothelioma Clinical Trial Near You
Get Help NowShare this article
Last Modified November 15, 2018
Daniel King
Writer
Daniel King joined Asbestos.com in 2017. He comes from a military family and attended high school on an Air Force base in Japan, so he feels a close connection to veterans, military families and the many hardships they face. As an investigative writer with interests in mesothelioma research and environmental issues, he seeks to educate others about the dangers of asbestos exposure to protect them from the deadly carcinogen. Daniel holds several certificates in health writing from the Centers for Disease Control and Prevention, and he is a member of the National Association of Science Writers.
2 Cited Article Sources
-
City of Hope. (n.d.). Marianna Koczywas, M.D.
Retrieved from: https://www.cityofhope.org/people/koczywas-marianna - ClinicalTrials.gov. (2018, April 24). Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin. Retrieved from: https://www.clinicaltrials.gov/ct2/show/NCT02535312
